Multicenter, rAndomized, Double-blind, Placebo-conTrolled, 52-week stUdy to demonstRatE the Efficacy, Safety and Tolerability of Secukinumab Injections With 2 mL Auto-injectors (300 mg) in Adult Subjects With Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms MATURE
- Sponsors Novartis Pharmaceuticals
- 28 Jan 2019 New source identified and integrated (European Clinical Trials Database EudraCT2018-000518-39 )
- 10 Jan 2019 Planned End Date changed from 11 May 2020 to 22 Jun 2020.
- 10 Jan 2019 Planned primary completion date changed from 5 Aug 2019 to 26 Sep 2019.